This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, F. Articles by Wada, H. Search for Related Content PubMed PubMed Citation Articles by Tanaka, F. Articles by Wada, H.

Prognostic Significance of Polysialic Acid Expression in Resected Non-Small Cell Lung Cancer¹

Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto 606-8507, [F. T., Y. O., T. N., Y. K., R. M., M. L., K. Y., K. In., H. O., T. Y., H. W.]; Central Clinical Laboratories, Shinshu University Hospital, Nagano 390-8621, [J. N.]; and Neuron Information Laboratory, National Institute for Physiological Sciences, Aichi 444-8585 [I. F., K. Ik.], Japan

Polysialic acid (PSA) is a carbohydrate attached mainly to the neural cell adhesion molecule. Because PSA is composed of a linear homopolymer of -2–8-linked sialic acid residues and has a large negative charge, the presence of PSA attenuates the adhesive property of neural cell adhesion molecule and increases cellular motility. In an earlier study, we demonstrated that PSA and STX, a polysialyltransferase, were associated with tumor progression in non-small cell lung cancer (NSCLC) (F. Tanaka et al., Cancer Res., 60: 3072–3080, 2000). Therefore, in the present study, to assess the prognostic significance of PSA in resected NSCLC, a total of 236 patients who underwent complete resection for pathological (p)-stage I-IIIa disease were reviewed retrospectively. PSA was expressed in 44 of 236 (18.6%) patients, and the expression was correlated with p-stage disease. For all p-stage patients, 5-year survival rates for those with PSA-positive and PSA-negative tumors were 52.1% and 71.3%, respectively, demonstrating a significantly worse prognosis for the PSA-positive patients (P = 0.012). Analysis for only p-stage I patients also demonstrated a significantly worse prognosis for the PSA-positive patients; 5-year survival rates of the PSA-positive and the PSA-negative patients were 45.1% and 83.5%, respectively, (P < 0.001). In addition, there proved to be no difference in the postoperative survival among p-stage I, II, and IIIa patients when PSA expression was positive. Multivariate analysis confirmed that PSA expression was an independent factor to predict poor prognosis in resected NSCLC. These results suggested that PSA could be an important clinical marker and that preoperative induction and/or postoperative adjuvant therapies should be performed for PSA-positive NSCLC, even if the disease is classified as p-stage I.

This article has been cited by other articles:

				T. Glaser, C. Brose, I. Franceschini, K. Hamann, A. Smorodchenko, F. Zipp, M. Dubois-Dalcq, and O. Brustle Neural Cell Adhesion Molecule Polysialylation Enhances the Sensitivity of Embryonic Stem Cell-Derived Neural Precursors to Migration Guidance Cues Stem Cells, December 1, 2007; 25(12): 3016 - 3025. [Abstract] [Full Text] [PDF]

				R. Seidenfaden, A. Krauter, F. Schertzinger, R. Gerardy-Schahn, and H. Hildebrandt Polysialic Acid Directs Tumor Cell Growth by Controlling Heterophilic Neural Cell Adhesion Molecule Interactions Mol. Cell. Biol., August 15, 2003; 23(16): 5908 - 5918. [Abstract] [Full Text] [PDF]

				U. Yabe, C. Sato, T. Matsuda, and K. Kitajima Polysialic Acid in Human Milk. CD36 IS A NEW MEMBER OF MAMMALIAN POLYSIALIC ACID-CONTAINING GLYCOPROTEIN J. Biol. Chem., April 11, 2003; 278(16): 13875 - 13880. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				M. Sok, M. Sentjurc, M. Schara, J. Stare, and T. Rott Cell membrane fluidity and prognosis of lung cancer Ann. Thorac. Surg., May 1, 2002; 73(5): 1567 - 1571. [Abstract] [Full Text] [PDF]

				A. Marchetti, N. Tinari, F. Buttitta, A. Chella, C. A. Angeletti, R. Sacco, F. Mucilli, A. Ullrich, and S. Iacobelli Expression of 90K (Mac-2 BP) Correlates with Distant Metastasis and Predicts Survival in Stage I Non-Small Cell Lung Cancer Patients Cancer Res., May 1, 2002; 62(9): 2535 - 2539. [Abstract] [Full Text] [PDF]